The investigational triple hormonal agonist retatrutide produced significant weight loss along with glycemic and cardiovascular improvements in adults with type 2 diabetes (T2D) and obesity, according ...

Viking Therapeutics tested various doses of its leading anti-obesity candidate, VK2735, administered subcutaneously every ...

The experimental weight-loss drug is a triple agonist and the first of its kind to reach a phase 3 clinical trial ...

Consumer guide finds no controlled human trial demonstrating that a baking soda water shot causes weight loss; current ...

Two studies found retatrutide helped participants lose significant weight, with Eli Lilly planning to seek FDA approval next ...

Eli Lilly and Company ( LLY) announced detailed results from the Phase 3 TRIUMPH-2 study showing that retatrutide delivered substantial weight loss and blood sugar improvements in adults living with ...

Novo Nordisk says its potential Wegovy successor helped patients lose more weight than Zepbound in a major clinical trial.

A new weekly weight loss drug helped patients lose up to 25% of body weight in studies. FDA approval could be sought next ...

Dr Roger Henderson explains how side effects and significant weight loss could disrupt sleep ...

Eli Lilly and Company ( LLY) reported detailed Phase 3 TRIUMPH-2 results showing that Retatrutide delivered substantial weight loss and blood sugar reductions in adults with obesity or overweight and ...

Before you switch from Wegovy to Zepbound or Ozempic, learn why weight loss plateaus happen and how long you should really ...

New medications to treat obesity have helped many people lose significant amounts of weight, but some of that weight loss inevitably comes from muscle loss. Ozempic, Wegovy, Mounjaro and Zepbound are ...